1. Home
  2. CINGW vs MGEE Comparison

CINGW vs MGEE Comparison

Compare CINGW & MGEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • MGEE
  • Stock Information
  • Founded
  • CINGW N/A
  • MGEE 1855
  • Country
  • CINGW United States
  • MGEE United States
  • Employees
  • CINGW 13
  • MGEE N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • MGEE Electric Utilities: Central
  • Sector
  • CINGW Health Care
  • MGEE Energy
  • Exchange
  • CINGW Nasdaq
  • MGEE Nasdaq
  • Market Cap
  • CINGW N/A
  • MGEE N/A
  • IPO Year
  • CINGW 2021
  • MGEE N/A
  • Fundamental
  • Price
  • CINGW $0.06
  • MGEE $90.52
  • Analyst Decision
  • CINGW
  • MGEE Sell
  • Analyst Count
  • CINGW 0
  • MGEE 1
  • Target Price
  • CINGW N/A
  • MGEE $74.00
  • AVG Volume (30 Days)
  • CINGW N/A
  • MGEE 106.3K
  • Earning Date
  • CINGW N/A
  • MGEE 10-31-2024
  • Dividend Yield
  • CINGW N/A
  • MGEE 1.99%
  • EPS Growth
  • CINGW N/A
  • MGEE 0.72
  • EPS
  • CINGW N/A
  • MGEE 3.19
  • Revenue
  • CINGW N/A
  • MGEE $645,729,000.00
  • Revenue This Year
  • CINGW N/A
  • MGEE $2.07
  • Revenue Next Year
  • CINGW N/A
  • MGEE $3.98
  • P/E Ratio
  • CINGW N/A
  • MGEE $28.38
  • Revenue Growth
  • CINGW N/A
  • MGEE N/A
  • 52 Week Low
  • CINGW N/A
  • MGEE $61.94
  • 52 Week High
  • CINGW N/A
  • MGEE $93.15
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • MGEE 54.51
  • Support Level
  • CINGW N/A
  • MGEE $88.21
  • Resistance Level
  • CINGW N/A
  • MGEE $91.03
  • Average True Range (ATR)
  • CINGW 0.00
  • MGEE 1.47
  • MACD
  • CINGW 0.00
  • MGEE -0.33
  • Stochastic Oscillator
  • CINGW 0.00
  • MGEE 51.68

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: